FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

GLENMARK Share Price Discussion

Glenmark Pharmaceuticals Ltd.
Sector: Pharmaceuticals and health care
... Read more
GLENMARK Share Price *
333.8 +2.75 (0.83%)
* (quote may be delayed)

Find answers to all your questions on live GLENMARK message board: Is GLENMARK buy or sell? Should I buy GLENMARK shares? Why are GLENMARK shares falling? Should I invest in GLENMARK stock?


You can also check GLENMARK share price target recommended by brokerages.

GLENMARK Discussion Forum


*performance on DAY THREE*
*Notional profits on DAY THREE ₹ 1,62,820.00*
*Futures & Options educational trades for the week 9.12.19 to 13.12.19*
(My trade rules apply)
The below trades are given for *educational* purposes and i am not responsible for any losses or profits.
Please...
Read more...
1
reply
Reply
share
Share
GLENMARK CMP 333 STOPLOSS 320 TARGET 370 for NSE:GLENMARK by CJS_SI
RISK 15 REWARD 35 6284263756 #Proof_N_Proved #WHAT_WE_SAY #WE_DELIVER #Nifty #nifty50 #NSEUpdates #niftyfuture #NSE #INVESTwithCJSSI #GUARANTEED_PROFIT_with_CJSSI #TARGET_ACHIEVED_with_CJSSI
TradingView
Like
reply
Reply
share
Share

buy glenmark cmp 332-333 sl 327.95 tgt 340-350
Like
reply
Reply (1)
share
Share
Latest replies
Pyramidstock @pyramidstock
Yesterday 4:34 PM

trading at cost exit

Positional Call: Buy Glenmark at 325-327
SL 318
Target 350 370
Like
reply
Reply (1)
share
Share
Latest replies
Intraday Trading Club @ITC
Yesterday 6:15 PM

335

INTRADAY BUY GLENMARK CMP 330 SL 322 TGT 336-345-350
Like
reply
Reply
share
Share

💠💠
YOUR FREE EQUITY CASH CALL FOR THIS FORUM TODAY:
BUY GLENMARK AT THE VERY BEGINING
STRICT STOP LOSS - 320
TARGET - 328/331/333
## GO WITH SAFER QUANTITY ##
Disclaimer: All my Views/Suggestions/Calls are for Education Purpose Only. Please consult with your financial adviser b...
Read more...
Like
reply
Reply
share
Share

Futures & Options educational trades for the week 9.12.19 to 13.12.19*
(My trade rules apply)
Glenmark* cmp 323.90 buy upto 301.00 stop 290.50 target 368.00+
Like
reply
Reply
share
Share

Now at 334.3 look good for buy, if come at 333.2-333.5 clear buy from my side
Like
reply
Reply
share
Share

buy noww
Like
reply
Reply (1)
share
Share
Latest replies
Mahesh Raja @maheshraja
Dec 6 3:23 PM

336

Buy GLENMARK 360 call 3.40-3 sl below 2 tgt open
Like
reply
Reply (1)
share
Share
Latest replies
veer @931648
Nov 27 6:54 PM

Hello brother

GLENMARK 💪💪Made ahigh 356.65 💉💉💉💉💉
Like
reply
Reply
share
Share
#Hansraj pandey in GLENMARK
BUY GLENMARK FUT @ 353.5 , STOP LOSS 350 , TAR...

GLENMARK 💪💪Made ahigh 356.65 💉💉💉💉💉
Like
reply
Reply
share
Share

BUY GLENMARK FUT @ 353.5 , STOP LOSS 350 , TARGET 360 / 375+
Like
reply
Reply
share
Share

BUY GLENMARK FUT @ 353.5 , STOP LOSS 350 , TARGET 360 / 375+
Like
reply
Reply
share
Share

Geojit Financial Services target on GLENMARK
Date: 25-Nov-19 Broker: Geojit Financial Services Price @ Call: 346.4 Target: 366 Recommendation: HOLD
1
reply
Reply
share
Share

Geojit Financial Services target on GLENMARK
Date: 25-Nov-19 Broker: Geojit Financial Services Price @ Call: 346.4 Target: 366 Recommendation: HOLD
1
reply
Reply
share
Share

Geojit Financial Services target on GLENMARK
Date: 25-Nov-19 Broker: Geojit Financial Services Price @ Call: 346.4 Target: 366 Recommendation: HOLD
Like
reply
Reply
share
Share

26-11-19
GLENMARK NOV PE 340 (Intraday)
only above 5.90
Like
reply
Reply (2)
share
Share
Latest replies
Sameer  @tradingfab
Nov 26 3:47 PM

High 6.45 ******************
Sameer  @tradingfab
Nov 26 3:48 PM

High 7.25 *******************
karan in GLENMARK
Sell glenmark at 342 for 338/335. SL 347.

Sorry it was by mistake. Ignore please
Like
reply
Reply
share
Share

Sell glenmark at 342 for 338/335. SL 347.
Like
reply
Reply
share
Share

BUY GLENMARK PHARAM CMP 355-354 SL 349.80 TGT 360-365-370
Like
reply
Reply
share
Share

INTRADAY BUY GLENMARK AT 352, TARGET 355, 257, SL 349
Like
reply
Reply (1)
share
Share
Latest replies

GLENMARK - 449162
GLENMARK DONE 352 TO 355, DELAYED UPDATE...
link
https://twitter.com/sachinsiwalRE/status/1197143596115386368/photo/1
t

GLENMARK - chart - 447402
#Glenmark rose more than 30% in last 5 trading sessions. Stock was traded in complete downtrend.
Now can you imagine what happened to those who are holding short positions without any hedge?
Successful trading is not just about booking profits. Risk management is also important ...
Read more...
Like
reply
Reply
share
Share

Buy-359
T-366
Sl-354
Like
reply
Reply
share
Share
link

charts fyers
Like
reply
Reply
share
Share

PC_-_Glenmark_Q2FY20_Update_-_Nov_2019_20191115175030.pdf
652 KB
Glenmark Pharma (GNP IN)
Core earnings concern remains
INDIA | PHARMACEUTICALS | Quarterly Update
Like
reply
Reply
share
Share

GLENMARK
My buy call Running from 290 to see the Blockbuster Move till 374
In Just 2 trading Sessions more than 30% Returns.
Now my view on GLENMARK
Cmp @ 353 spot
Every dip is Opportunity to buy for short term tgt 365-375++
SL @ your own risk or For Technical levels ping me
R...
Read more...
1
reply
Reply
share
Share
consistent Trader in GLENMARK
Glenmark fut sell 356 Target 350-49 SL 360 *...

Made a low of 352.6

Currently trading at 355.5

One can exit,no movement in stock.
Like
reply
Reply
share
Share

Glenmark fut sell 356

Target 350-49

SL 360

*Risky Trade*
Like
reply
Reply
share
Share
Hansraj pandey in GLENMARK
BUY GLENMARK FUTU 368-70 STOP LOSS 365 TARGE...

Avoid
Like
reply
Reply
share
Share

BUY GLENMARK FUTU 368-70 STOP LOSS 365 TARGET 375/380 #glenmark
Like
reply
Reply
share
Share

Risky
Sell glenmark pharma cash
367-371
Sl 375
Tgt 363/359
1
reply
Reply (2)
share
Share
Latest replies
DREAM BIG VIEW @dreambig
Nov 19 3:00 PM

Look at glenmark guys
367 to 360
Tgt 1 dn 363
Almost Tgt 2 dn 359
7 points good morning gain
Enjoy
🎉🎉🎉🎉🎉🎉
DREAM BIG VIEW @dreambig
Nov 19 5:32 PM

Sell glenmark
Update 367 to 354
All Tgt overachieved

BUY GLENMARK FUTU 368-70 STOP LOSS 365 TARGET 375/380
Like
reply
Reply
share
Share

GLENMARK - 443513
My trade on Glen..from 448 to 462
But didn't recommend... because...my previous calls were not satisfactory...
Like
reply
Reply
share
Share
Hustle With Ichimoku in GLENMARK
Glenmark Bullish (cmp 301) for 320

GLENMARK - 443470
#glenmark 301 to 365 ( unexpected move ) my target was 320 only
Like
reply
Reply
share
Share
Hansraj pandey in GLENMARK
RISKY TRADER DO TRADE GLENMARK 380 CE @7.50-...

GLENMARK New High 11.20💪💪🏃🏃🏃🏃💉💉💉
Like
reply
Reply
share
Share
Hansraj pandey in GLENMARK
RISKY TRADER DO TRADE GLENMARK 380 CE @7.50-...

GLENMARK 😍😍😍🚀🚀🚀🧬🔬💉🧬🔬💉
Like
reply
Reply
share
Share

RISKY TRADER DO TRADE GLENMARK 380 CE @7.50-8 STOP LOSS AND TARGET CLOSING BASIS
Like
reply
Reply
share
Share

Sell GLENMARK future 361 sl above 364.95 tgt 348, 342
Like
reply
Reply
share
Share
Hustle With Ichimoku in GLENMARK
#glenmark 310 CE at 8 Target 2x

310 CE 23.50
1
reply
Reply
share
Share

Glenmark 310 pe buy 6.60 target 8'10.12 sl4
Like
reply
Reply
share
Share
Hustle With Ichimoku in GLENMARK
Glenmark Bullish (cmp 301) for 320

#glenmark 310 CE at 8 Target 2x
Like
reply
Reply
share
Share

GLENMARK - 441434
Glenmark Bullish (cmp 301) for 320
Like
reply
Reply
share
Share

BUY GLENMARK PHARAM CMP 296-295 SL 289 TGT 301-308-318
Like
reply
Reply (3)
share
Share
Latest replies
Pyramidstock @pyramidstock
Nov 15 6:17 PM

301+ 1ST TGT DONE ENJOY
Pyramidstock @pyramidstock
Nov 15 6:21 PM

303+ SAFE PLAEYER BOOK RISKYONE KEEP HOLD WITH OLD SL FOR ATLEASR 308-10
Pyramidstock @pyramidstock
Nov 18 6:11 PM

I HOPE YOU ENJOYED THIS JACKPOT TRADE GUYS
Hansraj pandey in GLENMARK
BUY GLENMARK 298 STOP LOSS 294 TARGET 304 /307....

🎯🎯🎯GLENMARK first target done book again huge profit 💪💪
Like
reply
Reply
share
Share

BUY GLENMARK 298 STOP LOSS 294 TARGET 304 /307.5 /310
Like
reply
Reply
share
Share

GLENMARK - 439734

Like
reply
Reply
share
Share

Nomura on Glenmark
Buy, TP Rs 653
Q2 - A strong Qt
Net sales/EBITDA/Net profit 5%/33%/124% ahead of est
Working capital improved, but higher capex & higher R&D spend have been a drag on cash flows
Like
reply
Reply
share
Share

Good set of numbers Topline 2800 cr Bottom line 255 cr
Like
reply
Reply
share
Share

GLENMARK PHARMACEUTICALS -RECEIVES ANDA APPROVAL FOR ADAPALENE AND BENZOYL PEROXIDE GEL, 0.1%/2.5%
Like
reply
Reply
share
Share
  • GLENMARK - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization14,876.17
    Enterprise Value17,679.79
    Price to Earnings14.67
    Price to Book Value1.43
    Return on Capital Employed0.11
    Return on Equity0.1
    Face Value1
    Dividend YieldNA
  • GLENMARK Share Price - Technicals

    keyboard_arrow_down
    GLENMARK - 52 Week High₹705.9
    GLENMARK - 52 Week Low₹267.25
  • GLENMARK - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    25-Nov-19Geojit Financial ServicesHold366
    25-Nov-19Geojit Financial ServicesHold366
    25-Nov-19Geojit Financial ServicesHold366
    3-Sep-19Geojit Financial ServicesSell338
    19-Aug-19HDFC SecuritiesBuy500
    GLENMARK Brokerage Price Target
  • GLENMARK Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Dec 11331.45335.6329.7334.1
    Dec 10329.45335.7327.5331.05
    Dec 9326.7331.75323327.65
    Dec 6328.2337.35322.65324.9
    Dec 5327.05331.15325.15327.8
  • GLENMARK Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹335.07
    30 Day Moving Average₹324.6
    50 Day Moving Average₹316.99
    100 Day Moving Average₹357.86
    200 Day Moving Average₹468.49
  • GLENMARK - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue6,4037,989.23-0.2
    Operating Profit1,3472,662.19-0.49
    Profit Before Tax1,2192,552.9-0.52
    Net Income1,0142,140.61-0.53
  • GLENMARK - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Shareholder's Funds10,3919,436.620.1
    Total Liabilities5,2694,790.480.1
    Total Assets15,66114,227.10.1
  • GLENMARK - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,124877.720.28
    Cash from Investing Activity-1,137-2,580.46-0.56
    Cash from Financing Activity-621,879.38-1.03
    Net Cash Flow-75176.64-1.42
  • GLENMARK - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.060.15
    Return on Equity0.10.23
    Return on Capital Employed0.110.22
  • GLENMARK - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.23
    3 Year CAGR Growth in Operating Profit0.04
    3 Year CAGR Growth in EBIDTA0.11
    3 Year CAGR Growth in Net Income0.01
    3 Yr CAGR Growth - Diluted EPS-0.03
  • GLENMARK - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue2.16
    5 Year CAGR Growth in Operating Profit3.05
    5 Year CAGR Growth in EBIDTA2.4
    5 Year CAGR Growth in Net Income1.63
    3 Yr CAGR Growth - Diluted EPS1.52
  • GLENMARK - Recent News

    keyboard_arrow_down
    NewsBot
    Oct 23 5:13 PM
    SBI Life, ICICI Pru, Siemens in MSCI India Index? Here's what Morgan Stanley thinks
    Moneycontrol
    NewsBot
    Oct 17 4:53 PM
    Glenmark Pharma gets USFDA nod for prostate cancer treatment drug
    Moneycontrol
    NewsBot
    Oct 14 9:48 PM
    Glenmark Q2 PAT may dip 46% YoY to Rs. 132.8 cr: Emkay
    Moneycontrol
    NewsBot
    Oct 9 3:48 PM
    Glenmark Pharma down 1% despite tentative USFDA nod for multiple sclerosis drug
    Moneycontrol
    NewsBot
    Oct 7 5:28 PM
    D-Street Buzz: Nifty Pharma falls 2%; Glenmark, Auro Pharma, Piramal Enterprises, Lupin touch 52-week lows
    Moneycontrol
    NewsBot
    Oct 7 3:23 PM
    Glenmark Pharma hits 52-week low on USFDA warning letter for Baddi facility
    Moneycontrol
    NewsBot
    Oct 7 2:13 PM
    Market Headstart: Nifty likely to open higher; HCL Tech, Biocon top buys
    Moneycontrol
    NewsBot
    Oct 7 1:13 PM
    Stocks in the news: Glenmark Pharma, Ashok Leyland, Lupin, VST Tillers, BEML, SPARC
    Moneycontrol
    NewsBot
    Oct 6 5:53 PM
    Pharma wrap: No respite for Glenmark, USFDA’s warning letter on Baddi facility adds to woes
    Moneycontrol
    NewsBot
    Sep 30 8:23 PM
    Glenmark gets Russian health ministry's nod to market allergic rhinitis tablets
    Moneycontrol
  • GLENMARK - Related Communities

    keyboard_arrow_down
    MCX:RBDPMOLEIN
    MCX:PEPPER
    MCX:CASTORSEED
    MCX:CARDAMOM
    MCX:BRASSPHY
    Affle (India) Limited
    MCX:COTTON
    SPICEJET LTD Sector: Transport
    IRCTC Sector: Miscellaneous
    Share and discuss algorithms, strateg...
  • GLENMARK - More Information

    keyboard_arrow_down

    Glenmark Pharmaceuticals Ltd:
    Glenmark Pharmaceuticals, a company that deals with pharmaceutical products, was established in 1977 by Gracias Saldanha which headquarter is in Mumbai, India. It manufactures generic drugs and various active pharmaceutical ingredients.
    The company was named after the name of his two sons, Glenn and Mark. In the beginning, the company used to sell the products in India, Africa, and Russia. The company came to the public in the year 1999, and also took some procedures and built its research facility for the first time. Glenmark Saldanha’s elder son Glenn had the invasion as the CEO of the company in 2001 after working at PricewaterhouseCoopers when he came back to India.
    In 2008, Glenmark became the fifth-biggest company for pharmaceuticals in India. Glenmark entered into the market of dermatology by launching ‘Candid Cream’. Dermatology is one of the key focus areas of Glenmark, until today.
    About Company Information:
    The company entered the market of dermatology by launching Candid Cream in 1979, at the very beginning. In 1980, the company began to export their products outside of the country. In 1983, it incorporated its manufacturing facility for the very first time at Nasik, Maharashtra.
    The R&D department was founded in the plant at Nasik in 1984. The company introduced Ascoril in the market in 1987. The company initiated operating its business in Srilanka, Afghanistan, Mauritius, and Kenya in 1989. It expanded the plant at Nasik in 1992. It integrated a wholly possessed subordinate company, Glenmark Exports Pvt Ltd to strengthen its position internationally in the market of pharmaceuticals in 1996.
    In Brazil, the company started to sell pharmaceutical products in 1999. The company entered into the segment of diabetes in 2000. The company initiated the business of manufacturing API in 2001. It obtained a facility of API manufacturing from Glaxosmithkline Pharmaceuticals at Ankleshwar, Gujarat in 2002. Glenmark has done its out-licensing deal for the first time to discover R&D in 2004.
    The company commissioned a new facility for manufacture at Baddi, Himachal Pradesh in 2005. It signed an out-licensing contract with Merk KGaA, Germany in 2006, for Melogliptin. The company received the approval of MHRA, the UK for their plant at Baddi in 2007.
    The company re-organized its business and integrated a company namely Glenmark Generics as its subordinate one in 2008. During 2009-10, it integrated Glenmark Generics B.V. in the Netherlands. Glenmark signed the Development Agreement with Forest Laboratories to collaborate on Novel Agents.
    The company made the announcement of launching a cream namely Hydrocortisone Butyrate in the US, in 2013. Glenmark brought together its two subsidiary companies which are Glenmark Generics Ltd. and Glenmark Access Ltd. with GPL in the year 2014. The company disclosed its approval and launching of Verapamil and Trandolapril Hydrochloride in 2015.
    Glenmark announced the strategic blueprint of its evolution to an innovation-led globally spread pharmaceutical organization on 19th December 2016. The blueprint bears its greater alignment of business spreading generics to give priority mostly to the research and development efforts in three core therapeutic sections: respiratory, oncology and dermatology.
    The company announced affirmative results for GSP 301 on 30th March 2017. The company has also announced that it has submitted an NDA to the FDA of US for Ryaltris, the respiratory pipeline candidate, which is basically a tentative fixed-dose nasal spray which is a combination of a steroid and an antihistamine that is used for treatment of seasonal allergic rhinitis (SAR) and it was announced on 22nd May 2018.
    The company announced on 19th June 2018 that the first supplemental Abbreviated New Drug Application (SANDA) was provided by the US Food and Drug Administration for the manufacturing facility of the company in Monroe, New Carolina. The Monroe facility in New Carolina is the first manufacturing plant of Glenmark in the US which is founded to manufacture various pharmaceutical products of fixed does. The company has made an investment of more than $100 million on that facility along with some planning of further development in upcoming years.
    How Glenmark Pharmaceuticals Ltd is categorised as Pharmaceuticals and Health Care Sector and Pharmaceuticals Industry.
    Pharmaceuticals and Health care sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more. The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Glenmark Pharmaceuticals Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Glenmark Pharmaceuticals Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.